<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04595825</url>
  </required_header>
  <id_info>
    <org_study_id>CM-101-PSC-101</org_study_id>
    <nct_id>NCT04595825</nct_id>
  </id_info>
  <brief_title>CM-101 in PSC Patients -The SPRING Study</brief_title>
  <official_title>A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial Evaluating The Safety And Efficacy Of CM-101 In Subjects With Primary Sclerosing Cholangitis- The SPRING Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ChemomAb Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ChemomAb Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the safety, tolerability and activity of CM-101 in patients&#xD;
      with Primary Sclerosing Cholangitis (PSC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alkaline Phosphatase Levels (ALP)</measure>
    <time_frame>15 weeks</time_frame>
    <description>Mean and percent change in ALP from baseline to Week 15</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Enhanced Liver Fibrosis (ELF)</measure>
    <time_frame>15 weeks</time_frame>
    <description>Mean change from baseline to Week 15 in Enhanced Liver Fibrosis (ELF) score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in liver enzymes</measure>
    <time_frame>15 weeks</time_frame>
    <description>Percent change from baseline over time in liver enzymes (ALT, AST and GGT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver fibrosis markers</measure>
    <time_frame>15 weeks</time_frame>
    <description>Change from baseline to Week 15 in liver fibrosis markers such as PRO-C3 and PRO-C5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK profile</measure>
    <time_frame>15 weeks</time_frame>
    <description>Measurement of the serum CM-101 levels following repeated CM-101 administrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug antibodies</measure>
    <time_frame>up to 27 weeks</time_frame>
    <description>Evaluation of the development of anti-drug antibodies (ADA) following repeated CM-101 administrations</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Primary Sclerosing Cholangitis</condition>
  <arm_group>
    <arm_group_label>CM-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CM-101</intervention_name>
    <description>CM-101, Monoclonal Ab blocking CCL24</description>
    <arm_group_label>CM-101</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of large duct PSC of &gt; 24 weeks' duration&#xD;
&#xD;
          -  No significant clinical concern for cholangiocarcinoma based on clinical, laboratory&#xD;
             or imaging findings&#xD;
&#xD;
          -  Subjects with concomitant IBD must have recent colonoscopy with biopsy confirming no&#xD;
             dysplasia or cancer.&#xD;
&#xD;
          -  Subjects with IBD must be in remission and have stable disease&#xD;
&#xD;
          -  ConMed stable ≥12 weeks prior to randomization (including stable dose)&#xD;
&#xD;
          -  Female subjects of childbearing potential, effective method of contraception from the&#xD;
             Screening visit to 18 weeks post last dose&#xD;
&#xD;
          -  Able to understand and sign ICF&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant causes or manifestations of sclerosing cholangitis other than&#xD;
             PSC&#xD;
&#xD;
          -  Patient that are planned for or post liver transplantation&#xD;
&#xD;
          -  Patients with evidence of liver cirrhosis&#xD;
&#xD;
          -  History of cholangiocarcinoma or a high clinical suspicion for cholangiocarcinoma&#xD;
&#xD;
          -  Pregnant or breast feeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Universitaetsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Strassburg, MD</last_name>
      <phone>4922828715260</phone>
      <email>melanie.neuhaus@ukb.uni-bonn.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann Wolfgang Goethe-Universitaet</name>
      <address>
        <city>Frankfurt am Main</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kathrin Sprinzl, MD</last_name>
      <email>bott@em.uni-frankfurt.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover (MHH)</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heiner Wedemeyer, MD</last_name>
      <phone>495115322730</phone>
      <email>olga.stoll@mh-hannover.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Jena</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philipp Reuken, MD</last_name>
      <email>anja.schauer@med.uni-jena.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Fakultät Mannheim der Universität Heidelberg</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andreas Teufel, MD</last_name>
      <email>jasmin.fabian@umm.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>LMU - Klinikum der Universitaet Muenchen</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Simon Hohenester, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Soroka MC - site P23</name>
      <address>
        <city>Be'er Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anat Nevo-Shor, MD</last_name>
      <phone>+972-52-4382066</phone>
      <email>KantorIr@clalit.org.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam MC - site P22</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ella Veitsman, MD</last_name>
      <phone>+972-50-2063155</phone>
      <email>v_ben-hakoon@rambam.health.gov.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hadassah Ein Kereme - site P21</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rifaat Safadi, Prof. MD</last_name>
      <phone>+972-(0)2-6778539</phone>
      <email>reemk@hadassah.org.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galilee Medical Center - site P24</name>
      <address>
        <city>Nahariya</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Assi Nimar, Prof. MD.</last_name>
      <phone>+972-4-9107748</phone>
      <email>NellyB@gmc.gov.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>EMMS Nazareth Hospital - site P26</name>
      <address>
        <city>Nazareth</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rifat Safadi, Prof. MD.</last_name>
      <phone>+972-2-6778539</phone>
      <email>ramighantous@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rabin MC - site P25</name>
      <address>
        <city>Petah Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amir Shlomai, MD</last_name>
      <phone>+972-50-7930305</phone>
      <email>rivkaha1@clalit.org.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust - site P05</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Palak Trivedi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation Trust - Addenbrookes Hospital - site P09</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Mells, MD</last_name>
      <phone>44-0-1223-245-151</phone>
      <email>abigail.ford@addenbrookes.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NHS Greater Glasgow and Clyde - site P03</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Barclay, MD</last_name>
      <phone>+44-141-211-4000</phone>
      <email>susanne.cathcart@ggc.scot.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>King's College Hospital NHS Foundation Trust - site P04</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deepak Joshi, MD</last_name>
      <phone>+44-0-203299-2504</phone>
      <email>adam.hossen-mamode@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Royal Free Hospital - site P01</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas Thorburn, Prof. MD</last_name>
      <phone>+ 44-20-3758-2000</phone>
      <email>wassy.fofana@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich University Hospital - site P06</name>
      <address>
        <city>Norwich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Rushbrook, MD</last_name>
      <phone>+44-0-1603-286286</phone>
      <email>vanessa.martin@nnuh.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nottingham Digestive Diseases Centre Biomedical Research Unit - site P02</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Ryder, MD</last_name>
      <phone>+44-115-924-9924</phone>
      <email>Nicola.Benetti@nuh.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emma Culver, MD</last_name>
      <email>loren.smith@ouh.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Plymouth Hospitals NHS Trust - Derriford Hospital - site P07</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Cramp, MD</last_name>
      <phone>+44-1752792725</phone>
      <email>susan.inniss@nhs.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Israel</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 7, 2020</study_first_submitted>
  <study_first_submitted_qc>October 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anti-fibrotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Cholangitis, Sclerosing</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

